Novocure Stock Dips As Q1 Earnings Miss Estimates, Higher Costs Hurt Bottom Line

  • Novocure Ltd NVCR first quarter of FY23 net revenues slumped 11.2% year over year to $122.18 million, missing the estimate of $127.28 million.
  • The oncology company registered an adjusted loss of $(0.50), missing the consensus of $(0.32).
  • Higher operating expenses(+38.1% Y/Y) weighed on the quarter under review. Costs rose on increased investments associated with geographic expansion, supply chain expansion, and information technology enhancements.
  • Gross profit in Q1 plunged 15.7% to $92.57 million, while margins slid 408 basis points to nearly 76%.
  • As of March 31, 2023, there were 3,467 active patients in therapy. 
  • In Q1, 1,496 prescriptions were received, +8% Y/Y. The Company said it received "the most prescriptions in its history in the U.S." 
  • "We look forward to a promising 2023 and the opportunity to reach many more patients who can benefit from the use of Tumor Treating Fields therapy", said Novocure CEO Asaf Danziger.
  • Price Action: NVCR shares are trading lower by 2.7% at $64.14 premarket on the last check Thursday.

 

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsEquitiesNewsGuidanceTop StoriesMarketsGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!